부산대학교 도서관

Background: Pre-apheresis CD34+ cell counts are known to be the most important predictive factor for a successful PBSC collection. We describe clinical factors that may influence the CD34+ yield, such as previous radiotherapy, intensity of previous chemotherapy, underlying disease, status of disease at collection and performance status (PS). Methods: 153 apheresis were performed in 71 patients from 1998 to 2000 using Cobe Spectra 7.0 (32 MM, 19 HD, 17 NHL, 1 AML, 1 Ewing Sarcoma, 1 Germ Cell Tumour), 37 males (52.1%) and 34 females (47.9%), with a median PS of 90% (40-100) and a median age of 48 yrs (11-66). Most patients (64.8%) received >6 cycles of chemotherapy with alkylating agents, and 30% received previous radiotherapy. Mobilization included cyclophosphamide 1.5g/m² IV and G-CSF 10 mg/Kg SC in 68 patients, while 2 patients received only G-CSF. Apheresis began if CD34+ count was >3/mL or leucocyte count >1000/mm³. Chemotherapy intensity was classified according to the number of cycles (< or >6) and the presence of alkylating agents or fludarabine. Apheresis variables were the pre-apheresis leucocyte count on the first day of collection, the number of apheresis and the time for neutrophil and platelet recovery (>500 and >20000/mm³, respectively). Results: Previous chemotherapy was associated with the CD34+ yield (p=0.014). Radiotherapy was not associated with the number of apheresis (p=0.18) or CD34+ yield (p=0.31). There was no correlation between CD34+ yield and status of disease (p=0.47), underlying disease (p=0.29), PS (p=0.16) or pre-apheresis leucocyte count (p=0.23). Conclusion: Intensity of previous chemotherapy was the most important predictive factor of CD34+ yield. Radiotherapy, underlying disease, performance status and status of disease at collection were not correlated with CD 34+ yield in our patients. [ABSTRACT FROM AUTHOR]